Gilead Sciences, Inc. (NASDAQ:GILD) Plans Quarterly Dividend of $0.79

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Tuesday, April 22nd, Wall Street Journal reports. Stockholders of record on Friday, June 13th will be paid a dividend of 0.79 per share by the biopharmaceutical company on Friday, June 27th. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Friday, June 13th.

Gilead Sciences has a payout ratio of 37.1% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Gilead Sciences to earn $8.11 per share next year, which means the company should continue to be able to cover its $3.16 annual dividend with an expected future payout ratio of 39.0%.

Gilead Sciences Price Performance

GILD stock opened at $110.09 on Wednesday. The company has a 50 day simple moving average of $105.36 and a 200 day simple moving average of $101.86. The stock has a market cap of $136.94 billion, a price-to-earnings ratio of 297.54, a P/E/G ratio of 0.71 and a beta of 0.29. Gilead Sciences has a 1 year low of $62.69 and a 1 year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.32) EPS. Research analysts anticipate that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the sale, the chief executive officer now owns 620,268 shares in the company, valued at $68,489,992.56. This represents a 1.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,000 shares of company stock worth $4,630,310 in the last quarter. Company insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

An institutional investor recently raised its position in Gilead Sciences stock. Brighton Jones LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,359 shares of the biopharmaceutical company’s stock after buying an additional 2,450 shares during the quarter. Brighton Jones LLC’s holdings in Gilead Sciences were worth $1,326,000 as of its most recent SEC filing. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on GILD. Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, April 25th. Piper Sandler boosted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Finally, Morgan Stanley boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.